Clinical trials: Stroke

CLEAR-III: Intraventricular Hemorrhage (IVH), Intracerebral Hemorrhage-type Stroke Evaluating accelerated Resolution of Intraventricular Hemorrhage.
  • Study patients with Intracerebral hemorrhage ICH, specifically in the ventricles of the brain, will receive the clot busting drug, tPA, or placebo via extraventricular drain (EVD).
  • The purpose of this study is hopefully to improve short and long term functional outcomes, decrease mortality, decrease ICU stays, critical care complications, support earlier EVD removal, lessen chance of infection, and lower the rate of needing permanent VP shunts.
Principal investigators: David Antezana, M.D., and Lisa Yanase, M.D.
Sponsor: Johns Hopkins University, NIH
For more information, please contact Monica Rodriguez, RN, clinical research coordinator, at 503-216-1190.

Blood Pressure Control Parameters for Intracerebral Hemorrhage Patients.
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH-II)

ATACH-II: A Phase III, Randomized, Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage (NINDS) ICH patients receiving Nicardipine, randomized (1:1) to 1 or 2 different BP parameters to determine the best standardized BP protocol.  Primary outcome measure to reduce death and disability rates at 90 days.

Elevated blood pressure (BP) is observed in 46%-75% of patients with Intracerebral Hemorrhage (ICH).  A variety of BP management protocols are in place for treatment of acute hypertension in ICH but lack appropriate evidence.  Elevated BP may predispose ICH patients to hematoma expansion, which may be an important cause of poor outcomes.  Since hematoma expansion occurs during a time frame when therapeutic intervention is feasible, the opportunity exists to reduce BP, which ultimately may reduce hematoma expansion and subsequent death and disability.
  • The purpose of this study is to determine the therapeutic benefit of intensively decreasing blood pressure compared with standard blood pressure treatment in reducing the proportion of patients with death and disability at 90 days, among subjects with Intracerebral Hemorrhage treated within 4.5 hours of symptom onset.
Principal investigator: Ted Lowenkopf, M.D.
Sponsor: National Institute of Neurological Disorders and the University of Minnesota
For more information, please contact Monica Rodriguez, R.N., clinical research coordinator, at 503-216-1190.